Omeros (NASDAQ:OMER) announced its earnings results on Friday. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.04), Fidelity Earnings reports. The company had revenue of $4.61 million during the quarter, compared to analyst estimates of $3.07 million. During the same quarter in the prior year, the firm posted ($0.16) EPS.
OMER stock traded down $3.00 during midday trading on Friday, hitting $13.02. 5,656,225 shares of the company’s stock were exchanged, compared to its average volume of 613,109. Omeros has a 12-month low of $8.36 and a 12-month high of $27.00. The company has a market capitalization of $793.47 million, a PE ratio of -16.48 and a beta of 3.79.
In other Omeros news, VP Marcia S. Kelbon sold 7,529 shares of Omeros stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $25.75, for a total transaction of $193,871.75. Following the sale, the vice president now directly owns 227,645 shares in the company, valued at approximately $5,861,858.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.10% of the stock is owned by insiders.
Several brokerages recently commented on OMER. Maxim Group reiterated a “buy” rating and set a $32.00 target price on shares of Omeros in a report on Friday. ValuEngine downgraded Omeros from a “buy” rating to a “hold” rating in a report on Saturday. HC Wainwright set a $34.00 target price on Omeros and gave the company a “buy” rating in a report on Monday, August 6th. BidaskClub upgraded Omeros from a “hold” rating to a “buy” rating in a report on Friday, August 17th. Finally, Zacks Investment Research downgraded Omeros from a “buy” rating to a “hold” rating in a report on Tuesday, July 31st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $27.56.
COPYRIGHT VIOLATION WARNING: This article was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://transcriptdaily.com/2018/11/10/omeros-omer-releases-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Read More: Capital Gains
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.